Tobira Therapeutics Inc
Most Recent
Company & Industry OverviewsAllergan Enters the Attractive NASH Market
Although hepatitis C is the most common cause resulting in liver transplants today, NASH (nonalcoholic steatohepatitis) will replace it by 2030.
Company & Industry OverviewsUnderstanding Gilead Sciences’ NASH Pipeline
Simtuzumab is Gilead Sciences’ (GILD) most advanced NASH (nonalcoholic steatohepatitis) anti-fibrotic product.